SVB Securities analyst Faisal Khurshid initiated coverage of Rain Oncology with an Outperform rating and $11 price target. The firm expects the Phase III MANTRA study of milademetan in DD-LPS to read out positive next quarter, and believes this opportunity alone justifies a higher valuation for the stock without considering potential success in other indications.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RAIN:
- Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress
- Rain Oncology management to meet virtually with Piper Sandler
- Rain Oncology price target lowered to $24 from $29 at Citi
- Rain Oncology price target lowered to $17 from $18 at Mizuho
- Rain Oncology price target raised to $19 from $12 at H.C. Wainwright
